Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lumora vs Medro

Lumora
Graded #205

Higher grade

vs+2.499999999999993
Medro
Graded #256

Lower grade

The verdict

Lumora takes it — 66.1/100 to 63.6/100.

Lumora grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lumora (Blue Skies MD LLC dba Lumora MD) is a physician-founded telehealth platform offering compounded semaglutide and tirzepatide in injectable and sublingual forms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +14
36
50
Dose & formulationMedro +2
75
77
Clinical oversightLumora +16
87
71
Labs & monitoringLumora +24
76
52
FulfillmentMedro +18
74
92
Contract termsLumora +22
55
33
Lumora · left barMedro · right bar

The numbers

MetricLumoraMedro
WeighScore66.1/10063.6/100
GradeCC
Scorecard rank#205#256
Semaglutide$199/mo (starting dose, plus a separate fee, compounded)$199/mo (compounded)
Tirzepatide$299/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Lumora

Graded #205 · C

Strengths

  • Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
  • Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
  • LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
  • Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
  • Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141

Where it loses points

  • Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
  • Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
  • Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
  • No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
  • Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list
Medro

Graded #256 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard